Publication
Title
Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer : an update
Author
Abstract
Bevacizumab is the first anti-angiogenic agent approved for the treatment of metastatic colorectal cancer. The need for patient selection before initiating therapy necessitates the study of various proteins expressed in metastatic colorectal cancer tissue as candidate predictive markers. Immunohistochemistry is a valuable, commonly available and cost-effective method to assess predictive biomarkers. However, it is subject to variations and therefore requires rigorous protocol standardizations. Furthermore, validated quantification methodologies to study these angiogenic elements have to be applied. Based on their function in tumor angiogenesis and their relation to the mechanism of action of bevacizumab, protein markers were divided in four groups: VEGF A-signaling proteins; other relevant angiogenesis factors; factors regarding the tumor microenvironment and tumor intrinsic markers. Conceivably, nimbly selecting a small but relevant group of therapy-guided patients by the appropriate combination of predictive biomarkers may confer great value to this angiogenic inhibitor.
Language
English
Source (journal)
Expert review of molecular diagnostics
Publication
2015
ISSN
1473-7159
1744-8352
DOI
10.1586/14737159.2015.993972
Volume/pages
15 :3 (2015) , p. 399-414
ISI
000350148500013
Pubmed ID
25585649
Full text (Publisher's DOI)
Full text (open access)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identifier
Creation 21.03.2015
Last edited 04.03.2024
To cite this reference